Hospital
Western Reserve Hospital, LLC
Western Reserve Hospital, LLC was paid $15.53M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoWESTERN RESERVE HOSPITAL, LLC
CUYAHOGA FALLS, OH 44223
CUYAHOGA FALLS, OH 44223
33aNPI1518104199assigned 01/19/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.53M
24GClaims367,634
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#61 of 101
Median peer was paid$22.32M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,136 | $1.83M | |
| 2019 | 31,971 | $1.30M | |
| 2020 | 19,744 | $1.13M | |
| 2021 | 25,929 | $1.31M | |
| 2022 | 23,315 | $1.09M | |
| 2023 | 148,982 | $6.24M | |
| 2024incomplete | 76,557 | $2.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 31,136 | 25,999 | $3.67M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 6,896 | 4,779 | $2.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 15,373 | 12,507 | $2.01M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 18,043 | 16,087 | $1.85M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.5% | 7,738 | 6,546 | $847K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 5,754 | 4,587 | $583K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 1,956 | 1,261 | $557K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,585 | 1,128 | $433K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 925 | 653 | $294K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 2,169 | 1,604 | $289K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 1,656 | 807 | $271K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 966 | 582 | $242K |
196 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 3,090 | $206K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 1,167 | $156K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,084 | $119K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 769 | $116K |
| 80053 | Comprehensive metabolic panel | <1% | 11,863 | $115K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,792 | $86K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 312 | $85K |
| 64635 | <1% | 203 | $67K | |
| G0378 | Hospital observation service, per hour | <1% | 927 | $66K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,749 | $63K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,819 | $57K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 121 | $53K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 869 | $45K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 167 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,261 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,156 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,204 | $36K |
| 80061 | Lipid panel | <1% | 2,110 | $35K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 198 | $34K |
| 20611 | <1% | 127 | $32K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,392 | $30K |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,711 | $28K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 82 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,149 | $26K |
| 97161 | <1% | 330 | $24K | |
| 84484 | <1% | 4,661 | $24K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 124 | $21K |
| 73630 | <1% | 1,101 | $21K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,830 | $20K |
| 64450 | <1% | 99 | $19K | |
| 86140 | <1% | 1,025 | $19K | |
| 73562 | <1% | 406 | $19K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 190 | $19K |
| 81001 | <1% | 11,982 | $16K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 34 | $16K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 727 | $16K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 232 | $16K |
| 73130 | <1% | 861 | $15K | |
| 97162 | <1% | 165 | $14K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,677 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,234 | $13K |
| 93975 | <1% | 73 | $12K | |
| 93971 | <1% | 108 | $12K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 50 | $12K |
| 73610 | <1% | 668 | $12K | |
| 73030 | <1% | 608 | $12K | |
| 82607 | <1% | 547 | $11K | |
| 81025 | <1% | 4,653 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 481 | $10K |
| 72100 | <1% | 349 | $10K | |
| 84439 | <1% | 420 | $10K | |
| 90715 | <1% | 523 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 685 | $9K |
| 64640 | <1% | 47 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,444 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 68 | $8K |
| 80076 | <1% | 968 | $8K | |
| 73110 | <1% | 447 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 91 | $8K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $7K |
| 85027 | <1% | 729 | $7K | |
| 73502 | <1% | 367 | $7K | |
| 64493 | <1% | 18 | $7K | |
| 83690 | <1% | 4,365 | $7K | |
| 85652 | <1% | 1,093 | $6K | |
| 82728 | <1% | 482 | $6K | |
| 83550 | <1% | 522 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,895 | $6K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 61 | $6K |
| 83540 | <1% | 572 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 124 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 93 | $5K |
| 73564 | <1% | 549 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 8,723 | $4K |
| 94729 | <1% | 56 | $4K | |
| 93017 | <1% | 53 | $4K | |
| 83970 | <1% | 130 | $4K | |
| 86900 | <1% | 193 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 19 | $4K |
| 64636 | <1% | 187 | $4K | |
| 83605 | <1% | 1,663 | $4K | |
| 94760 | <1% | 912 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,006 | $4K |
| 12001 | <1% | 21 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,158 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 42 | $3K |
| 72110 | <1% | 77 | $3K | |
| 83735 | <1% | 886 | $3K | |
| 96367 | <1% | 78 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 24 | $3K |
| 82570 | <1% | 337 | $3K | |
| 10060 | <1% | 17 | $3K | |
| 97113 | <1% | 47 | $2K | |
| 80320 | <1% | 512 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16 | $2K |
| J3490 | Unclassified drugs | <1% | 2,923 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,007 | $2K |
| 94726 | <1% | 38 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,919 | $2K |
| 82746 | <1% | 186 | $2K | |
| 85610 | <1% | 895 | $2K | |
| 73565 | <1% | 65 | $2K | |
| 80069 | <1% | 63 | $2K | |
| 86850 | <1% | 112 | $2K | |
| 73080 | <1% | 77 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 2,171 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 779 | $1K |
| 71250 | <1% | 30 | $1K | |
| 87486 | <1% | 773 | $1K | |
| 84702 | <1% | 134 | $1K | |
| 73560 | <1% | 65 | $1K | |
| 87186 | <1% | 672 | $1K | |
| 87581 | <1% | 773 | $1K | |
| 82962 | <1% | 1,304 | $1K | |
| 0012A | <1% | 40 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,883 | $1K |
| 83880 | <1% | 444 | $1K | |
| 82043 | <1% | 172 | $1K | |
| 87088 | <1% | 527 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 59 | $1K |
| 0011A | <1% | 39 | $996.01 | |
| 87430 | <1% | 1,570 | $959.96 | |
| 73590 | <1% | 22 | $879.52 | |
| 74018 | <1% | 60 | $876.48 | |
| 81003 | <1% | 633 | $843.13 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 271 | $743.76 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 557 | $704.73 |
| 64615 | <1% | 15 | $692.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,385 | $687.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,733 | $650.56 |
| 84703 | <1% | 510 | $649.87 | |
| 86038 | <1% | 34 | $612.46 | |
| 87070 | <1% | 93 | $515.02 | |
| 85379 | <1% | 616 | $512.72 | |
| 96376 | <1% | 860 | $509.91 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,878 | $487.87 |
| 87081 | <1% | 1,021 | $414.87 | |
| 90686 | <1% | 31 | $395.60 | |
| 85730 | <1% | 199 | $386.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,044 | $369.84 |
| 88304 | <1% | 212 | $368.46 | |
| 84156 | <1% | 61 | $358.69 | |
| 86901 | <1% | 278 | $347.51 | |
| 76830 | Ultrasound, transvaginal | <1% | 17 | $343.83 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,860 | $315.34 |
| 87205 | <1% | 40 | $304.26 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 842 | $297.86 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 214 | $294.04 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 149 | $239.17 |
| G0008 | Administration of influenza virus vaccine | <1% | 51 | $237.35 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 284 | $222.49 |
| 84153 | <1% | 13 | $184.59 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,315 | $170.84 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,845 | $169.98 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,999 | $139.97 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 368 | $132.79 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 401 | $131.31 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 176 | $129.50 |
| 82565 | <1% | 15 | $126.66 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 277 | $117.17 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,478 | $117.07 |
| 00731 | <1% | 271 | $115.94 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 125 | $115.86 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 365 | $107.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 397 | $101.10 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 862 | $89.11 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 853 | $88.64 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 151 | $86.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 896 | $75.07 |
| 82550 | <1% | 25 | $70.50 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 675 | $58.39 |
| 87210 | <1% | 34 | $54.31 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 127 | $48.17 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 640 | $45.54 |
| 36416 | <1% | 1,073 | $45.04 | |
| 81002 | <1% | 39 | $41.82 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 373 | $30.13 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 63 | $29.91 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 644 | $27.92 |
| 84100 | <1% | 24 | $27.51 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 261 | $23.63 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 47 | $16.95 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 79 | $7.15 |
| A9270 | Non-covered item or service | <1% | 2,785 | $2.94 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 48 | $1.90 |
| 91301 | <1% | 84 | $0.55 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 36 | $0.00 |
| 64494 | 0% | 18 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 28 | $0.00 |
| 76942 | 0% | 67 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 25 | $0.00 |
| 87400 | 0% | 241 | $0.00 | |
| 87420 | 0% | 69 | $0.00 | |
| 00811 | 0% | 126 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENT, ROBERT (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| WRH Physicians, INC. | Stow, OH | $201K |
| Kadia Medical, LLC | Deltona, FL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.